hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ??50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy[1].
hCAI/II-IN-6 (0-50 μM) inhibits hCA I, hCA II , hCA VII and hCA XII activities with Ki values of 220, 4.9, 6.5 and ??50000 nM, respectively[1].
hCAI/II-IN-6 (30-100mg/kg; i.p. once) shows good anticonvulsant effect in vivo[1].
hCAI/II-IN-6 (30 mg/kg; p.o. once) shows anti-MES activity in vivo[1].